Celltrion

About Celltrion

A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector.

The company has pioneered numerous uncharted areas to stellar success, which it plans to follow up by continuing its growth as a global biopharmaceutical company with unique approaches to small molecule pharmaceuticals and new businesses such as the Ubiquitous-healthcare platform business.

Read more Show less
Certifications
  • FDA
    FDA
  • GMP
    GMP
  • ISO
    ISO
  • Other
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • KR
  • 2022
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
Primary activities
Biopharmaceutical
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024
View Exhibitor Profile

Products from Celltrion (5)

  • Remsima SC

    Product Remsima SC

    The 1st subcutaneous formulation of infliximab • Ingredient: Infliximab  • Indication: Rheumatoid arthritis, inflammatory bowel disease • Mode of mechanism: Alleviate disease progression by inducing a neutralizing reaction to TNF-α, the cause of autoimmune disease • Approval status: 49 countries in...
  • Remsima

    Product Remsima

    The world's 1st mAb biosimilar • Ingredient: Infliximab • Indication: Rheumatoid arthritis, inflammatory bowel disease • Mode of mechanism: Relieves disease progression by inducing a neutralizing response to tumor necrosis factor(TNF-α), the cause of autoimmune disease • Approval status: 100 countri...
  • Truxima

    Product Truxima

    • Ingredient: Rituximab • Indication: Non-Hodgkin's lymphoma, rheumatoid arthritis • Mode of mechanism: Specifically binds to CD20, which is expressed on the cell surface of human B cells and lyses target cells to express pharmacological action with mechamisms such as complement-dependent cytotoxicity, ...
  • Herzuma

    Product Herzuma

    • Ingredient: Trastuzumab • Indication: Breast cancer, stomach cancer • Mode of mechanism: Inhibits tumor cell proliferation and growth by binding to a specific antigen (HER2) that occurs specifically and excessively on the surface of tumor cells  • Approval status: 80 countries including US, Euro...
  • Yuflyma

    Product Yuflyma

    • Ingredient: Adalimumab • Indication: Rheumatoid arthritis, inflammatory bowel disease • Mode of mechanism: Blocks the transmission of inflammatory signals by binding to TNF-α in the body   • Approval status: 44 countries including the US(product name: Inflectra), Europe and South Korea 

Celltrion Resources (2)